Immunocore (IMCR) Projected to Post Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is anticipated to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Immunocore to post earnings of ($0.31) per share and revenue of $87.63 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Immunocore Price Performance

Shares of IMCR stock opened at $29.92 on Monday. The stock has a 50-day moving average price of $29.97 and a 200 day moving average price of $32.08. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -31.49 and a beta of 0.77. Immunocore has a 12 month low of $27.69 and a 12 month high of $72.56.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IMCR shares. Morgan Stanley restated an “equal weight” rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research note on Friday, January 10th. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and cut their target price for the company from $72.00 to $38.00 in a research note on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.